Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Michail Doukas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8611-840X; OpenAlex author ID A5104332060, A5109167654. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
89
Papers, trials and grants by year

2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: 4 papers · 2025: 5 papers · 2026: 3 papers

Papers 20

  1. Pancreatic Ductal Adenocarcinoma with Atypical Genomic Profile: A Case of Long-Term Survival with KRAS-Wildtype, Microsatellite Instability and High Tumor Muta… First author DOI 10.1159/000552404↗
  2. Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model. Co-author DOI 10.1186/s13550-026-01372-5↗
  3. Bremachlorin-Based Photodynamic-Therapy-Induced Effects in Low-Oxygenated Pancreatic Ductal Adenocarcinoma (PDAC) Tumor Microenvironment. Co-author DOI 10.3390/ijms27209374↗
  4. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Co-author DOI 10.1016/j.ejca.2025.116065↗
  5. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  6. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Co-author DOI 10.1038/s41467-025-66092-1↗
  7. Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. Co-author DOI 10.1038/s41598-025-94362-x↗
  8. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  9. Rapid Assessment of Bio-distribution and Antitumor Activity of the Photosensitizer Bremachlorin in a Murine PDAC Model: Detection of PDT-induced Tumor Necrosis… Co-author DOI 10.1007/s11307-024-01921-1↗
  10. GATA6 identifies an immune-enriched phenotype linked to favorable outcomes in patients with pancreatic cancer undergoing upfront surgery. Co-author DOI 10.1016/j.xcrm.2024.101557↗
  11. Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-75888-y↗
  12. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1200/jco.23.02585↗
  13. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer. Co-author DOI 10.1002/ijc.34276↗
  14. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. Co-author DOI 10.1016/j.hpb.2023.04.018↗
  15. Nationwide Impact of Centralization, Neoadjuvant Therapy, Minimally Invasive Surgery, and Standardized Pathology Reporting on R0 Resection and Overall Survival… Co-author DOI 10.1245/s10434-023-13465-9↗
  16. Rintatolimod: a potential treatment in patients with pancreatic cancer expressing Toll-like receptor 3. Co-author PMID 37424830↗
  17. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I stud… Co-author DOI 10.1016/j.ejca.2022.03.015↗
  18. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen-Letter. Last author DOI 10.1158/1078-0432.ccr-21-2257↗
  19. Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer: Pathological Assessment and Recurrence Patterns. Co-author DOI 10.1097/mpa.0000000000001897↗
  20. Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1681↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 14 shared papers, 2021–2026 · strength 2.55
  2. Bas Groot Koerkamp · 8 shared papers, 2021–2025 · strength 1.30
  3. Marc G. Besselink · 6 shared papers, 2021–2025 · strength 0.92
  4. Ignace H. J. T. de Hingh · 5 shared papers, 2023–2025 · strength 0.86
  5. Judith de Vos‐Geelen · 4 shared papers, 2025 · strength 0.78
  6. Bert A. Bonsing · 5 shared papers, 2021–2025 · strength 0.74
  7. Marjolein Y.V. Homs · 4 shared papers, 2023–2025 · strength 0.73
  8. Johanna W. Wilmink · 3 shared papers, 2023–2026 · strength 0.70
  9. Marco J. Bruno · 4 shared papers, 2022–2025 · strength 0.63
  10. Joanne Verheij · 4 shared papers, 2021–2025 · strength 0.61
  11. Casper W.F. van Eijck · 3 shared papers, 2023–2025 · strength 0.60
  12. Gaby J. Strijk · 2 shared papers, 2025–2026 · strength 0.56
  13. Dana A. M. Mustafa · 3 shared papers, 2022–2024 · strength 0.54
  14. Laura Mezzanotte · 2 shared papers, 2024–2026 · strength 0.52
  15. Clemens W.G.M. Löwik · 2 shared papers, 2024–2026 · strength 0.52
  16. Roisin McMorrow · 2 shared papers, 2024–2026 · strength 0.52
  17. Dominic J. Robinson · 2 shared papers, 2024–2026 · strength 0.52
  18. Lodewijk A.A. Brosens · 3 shared papers, 2023–2025 · strength 0.52
  19. Freek R. van ‘t Land · 3 shared papers, 2021–2025 · strength 0.49
  20. Vincent Erwin de Meijer · 2 shared papers, 2025 · strength 0.38
  21. Lara Rosaline Heij · 2 shared papers, 2025 · strength 0.36
  22. Marcella Willemsen · 2 shared papers, 2024–2025 · strength 0.36
  23. Elham Aïda Farshadi · 2 shared papers, 2021–2024 · strength 0.36
  24. Lydia G. van der Geest · 2 shared papers, 2023–2025 · strength 0.35
  25. Hjalmar C. van Santvoort · 2 shared papers, 2023–2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.